港股18A现首例反向收购案,嘉和生物寻求自救

国际金融报
09 Oct 2024

今年以来,并购重组市场持续活跃,并成为重要趋势。  近日,港股18A市场出现了首个反向收购案例:嘉和生物宣布收购CSO(合同销售组织)企业亿腾医药。收购完成后,嘉和生物更名为亿腾嘉和医药集团有限公司(下称“亿腾嘉和”),亿腾医药实际控制人倪昕为新公司的控股股东。  在业内看来,此次反向收购是双赢之举。嘉和生物虽然是昔日的“明星”biotech(生物科技企业),但近年来发展受阻,上市4年至今仍未盈利...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10